BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Keck ZY, Pierce BG, Lau P, Lu J, Wang Y, Underwood A, Bull RA, Prentoe J, Velázquez-Moctezuma R, Walker MR, Luciani F, Guest JD, Fauvelle C, Baumert TF, Bukh J, Lloyd AR, Foung SKH. Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design. PLoS Pathog 2019;15:e1007772. [PMID: 31100098 DOI: 10.1371/journal.ppat.1007772] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Nishio A, Hasan S, Park H, Park N, Salas JH, Salinas E, Kardava L, Juneau P, Frumento N, Massaccesi G, Moir S, Bailey JR, Grakoui A, Ghany MG, Rehermann B. Serum neutralization activity declines but memory B cells persist after cure of chronic hepatitis C. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-33035-z] [Reference Citation Analysis]
2 Bozhanova NG, Flyak AI, Brown BP, Ruiz SE, Salas J, Rho S, Bombardi RG, Myers L, Soto C, Bailey JR, Crowe JE, Bjorkman PJ, Meiler J. Computational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-30865-9] [Reference Citation Analysis]
3 Pfaff-Kilgore JM, Davidson E, Kadash-Edmondson K, Hernandez M, Rosenberg E, Chambers R, Castelli M, Clementi N, Mancini N, Bailey JR, Crowe JE Jr, Law M, Doranz BJ. Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening. Cell Rep 2022;39:110859. [PMID: 35613596 DOI: 10.1016/j.celrep.2022.110859] [Reference Citation Analysis]
4 Wang R, Suzuki S, Guest JD, Heller B, Almeda M, Andrianov AK, Marin A, Mariuzza RA, Keck ZY, Foung SKH, Yunus AS, Pierce BG, Toth EA, Ploss A, Fuerst TR. Induction of broadly neutralizing antibodies using a secreted form of the hepatitis C virus E1E2 heterodimer as a vaccine candidate. Proc Natl Acad Sci U S A 2022;119:e2112008119. [PMID: 35263223 DOI: 10.1073/pnas.2112008119] [Reference Citation Analysis]
5 Hamley IW. Peptides for Vaccine Development. ACS Appl Bio Mater 2022. [PMID: 35195008 DOI: 10.1021/acsabm.1c01238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhang H, Quadeer AA, McKay MR. Evolutionary modeling reveals enhanced mutational flexibility of HCV subtype 1b compared with 1a. iScience 2022;25:103569. [PMID: 34988406 DOI: 10.1016/j.isci.2021.103569] [Reference Citation Analysis]
7 Pihl AF, Feng S, Offersgaard A, Alzua GP, Augestad EH, Mathiesen CK, Jensen TB, Krarup H, Law M, Prentoe J, Christensen JP, Bukh J, Gottwein JM. Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice. J Hepatol 2022:S0168-8278(21)02303-5. [PMID: 34990750 DOI: 10.1016/j.jhep.2021.12.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Bukh J. Neutralizing Antibodies Against Hepatitis C Virus and Their Role in Vaccine Immunity. Gastroenterology 2021:S0016-5085(21)03809-9. [PMID: 34863787 DOI: 10.1053/j.gastro.2021.11.033] [Reference Citation Analysis]
9 Pantazica AM, Cucos LM, Stavaru C, Clarke JL, Branza-Nichita N. Challenges and Prospects of Plant-Derived Oral Vaccines against Hepatitis B and C Viruses. Plants (Basel) 2021;10:2037. [PMID: 34685844 DOI: 10.3390/plants10102037] [Reference Citation Analysis]
10 Ahsan A, Dar S, Hassan F, Ghafoor F, Yousuf MH, Shahzad-Ul-Hussan S. Characterization of linear epitope specificity of antibodies potentially contributing to spontaneous clearance of hepatitis C virus. PLoS One 2021;16:e0256816. [PMID: 34449828 DOI: 10.1371/journal.pone.0256816] [Reference Citation Analysis]
11 Augestad EH, Bukh J, Prentoe J. Hepatitis C virus envelope protein dynamics and the link to hypervariable region 1. Curr Opin Virol 2021;50:69-75. [PMID: 34403905 DOI: 10.1016/j.coviro.2021.07.006] [Reference Citation Analysis]
12 Prentoe J, Janitzek CM, Velázquez-Moctezuma R, Goksøyr L, Olsen RW, Fanalista M, Augestad EH, Thrane S, Pihl AF, Gottwein JM, Sander AF, Bukh J. Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens. PLoS One 2021;16:e0255336. [PMID: 34329365 DOI: 10.1371/journal.pone.0255336] [Reference Citation Analysis]
13 Brasher NA, Adhikari A, Lloyd AR, Tedla N, Bull RA. Hepatitis C Virus Epitope Immunodominance and B Cell Repertoire Diversity. Viruses 2021;13:983. [PMID: 34070572 DOI: 10.3390/v13060983] [Reference Citation Analysis]
14 Guest JD, Wang R, Elkholy KH, Chagas A, Chao KL, Cleveland TE 4th, Kim YC, Keck ZY, Marin A, Yunus AS, Mariuzza RA, Andrianov AK, Toth EA, Foung SKH, Pierce BG, Fuerst TR. Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer. Proc Natl Acad Sci U S A 2021;118:e2015149118. [PMID: 33431677 DOI: 10.1073/pnas.2015149118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
15 Guest JD, Pierce BG. Structure-Based and Rational Design of a Hepatitis C Virus Vaccine. Viruses 2021;13:837. [PMID: 34063143 DOI: 10.3390/v13050837] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Yechezkel I, Law M, Tzarum N. From Structural Studies to HCV Vaccine Design. Viruses 2021;13:833. [PMID: 34064532 DOI: 10.3390/v13050833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Schlotthauer F, McGregor J, Drummer HE. To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity. Viruses 2021;13:805. [PMID: 33946211 DOI: 10.3390/v13050805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Velázquez-Moctezuma R, Augestad EH, Castelli M, Holmboe Olesen C, Clementi N, Clementi M, Mancini N, Prentoe J. Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies. Vaccines (Basel) 2021;9:291. [PMID: 33804732 DOI: 10.3390/vaccines9030291] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Chen F, Tzarum N, Lin X, Giang E, Velázquez-Moctezuma R, Augestad EH, Nagy K, He L, Hernandez M, Fouch ME, Grinyó A, Chavez D, Doranz BJ, Prentoe J, Stanfield RL, Lanford R, Bukh J, Wilson IA, Zhu J, Law M. Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins. Immunity 2021;54:781-796.e4. [PMID: 33675683 DOI: 10.1016/j.immuni.2021.02.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
20 Law M. Antibody Responses in Hepatitis C Infection. Cold Spring Harb Perspect Med 2021;11:a036962. [PMID: 32341067 DOI: 10.1101/cshperspect.a036962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Stuart JD, Salinas E, Grakoui A. Immune system control of hepatitis C virus infection. Curr Opin Virol. 2021;46:36-44. [PMID: 33137689 DOI: 10.1016/j.coviro.2020.10.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Tzarum N, Giang E, Kadam RU, Chen F, Nagy K, Augestad EH, Velázquez-Moctezuma R, Keck ZY, Hua Y, Stanfield RL, Dreux M, Prentoe J, Foung SKH, Bukh J, Wilson IA, Law M. An alternate conformation of HCV E2 neutralizing face as an additional vaccine target. Sci Adv 2020;6:eabb5642. [PMID: 32754640 DOI: 10.1126/sciadv.abb5642] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
23 Sepulveda-Crespo D, Resino S, Martinez I. Hepatitis C virus vaccine design: focus on the humoral immune response. J Biomed Sci 2020;27:78. [PMID: 32631318 DOI: 10.1186/s12929-020-00669-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Yamamoto C, Nagashima S, Chuon C, Ko K, Huy Do S, Lim O, Hok S, Svay S, Matsuo J, Katayama K, Takahashi K, Tanaka J. Substitution of the CD81 Binding Site and β-Sandwich Area in E2 of HCV in Cambodia. Viruses 2020;12:E551. [PMID: 32429467 DOI: 10.3390/v12050551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 He L, Tzarum N, Lin X, Shapero B, Sou C, Mann CJ, Stano A, Zhang L, Nagy K, Giang E, Law M, Wilson IA, Zhu J. Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines. Sci Adv 2020;6:eaaz6225. [PMID: 32494617 DOI: 10.1126/sciadv.aaz6225] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]
26 Flyak AI, Ruiz SE, Salas J, Rho S, Bailey JR, Bjorkman PJ. An ultralong CDRH2 in HCV neutralizing antibody demonstrates structural plasticity of antibodies against E2 glycoprotein. Elife 2020;9:e53169. [PMID: 32125272 DOI: 10.7554/eLife.53169] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
27 Stejskal L, Lees WD, Moss DS, Palor M, Bingham RJ, Shepherd AJ, Grove J. Flexibility and intrinsic disorder are conserved features of hepatitis C virus E2 glycoprotein. PLoS Comput Biol 2020;16:e1007710. [PMID: 32109245 DOI: 10.1371/journal.pcbi.1007710] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
28 Minafò YA, Del Padre M, Cristofoletti C, Caprini E, Perez M, Aranburu A, Colantuono S, Gragnani L, Zignego AL, Pulsoni A, Di Napoli A, Casato M, Fiorilli M, Visentini M. A stereotyped light chain may shape virus-specific B-cell receptors in HCV-dependent lymphoproliferative disorders. Genes Immun 2020;21:131-5. [PMID: 32066891 DOI: 10.1038/s41435-020-0093-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
29 Malonis RJ, Lai JR, Vergnolle O. Peptide-Based Vaccines: Current Progress and Future Challenges. Chem Rev 2020;120:3210-29. [PMID: 31804810 DOI: 10.1021/acs.chemrev.9b00472] [Cited by in Crossref: 84] [Cited by in F6Publishing: 66] [Article Influence: 28.0] [Reference Citation Analysis]
30 Kinchen VJ, Massaccesi G, Flyak AI, Mankowski MC, Colbert MD, Osburn WO, Ray SC, Cox AL, Crowe JE Jr, Bailey JR. Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance. J Clin Invest 2019;129:4786-96. [PMID: 31408439 DOI: 10.1172/JCI130720] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
31 [DOI: 10.1101/2021.03.21.436311] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]